top of page

The Potential Role of Amyloid Beta Peptides Concussion Biomarkers Reported

Increased levels of circulating amyloid beta (abeta) - 40 and -42 peptides are often increased after concussion. As such, these peptides are promising blood biomarkers of post-concussive events and neurological damage. Concussion-like symptoms are also associated with increased abeta in peripheral blood after blast exposure devoid of a clinically defined injury. A recently published review and opinion article highlights recent work describing abeta elevation in peripheral blood among persons with probable or diagnosed concussion. The authors propose utility of abeta to augment clinical examination or provide rationale for continuous, post-event monitoring.

These studies were originally featured in

Frontiers Neurology, Neurotrauma - Insights in Neurotrauma: 2021

“Opinion: The Potential Role of Amyloid Beta Peptides as Biomarkers of Subconcussion and Concussion”

Angela M Boutté, Ph.D., Bharani Thangavelu, Ph.D., and John Anagli, Ph.D.

Aries Biotech is a neurological disease and dementia biomarker consulting company.

To learn how we can augment your needs, visit Aries Biotech at

16 views0 comments

Recent Posts

See All

Are you interested in #biomarkers and #therapeutics for #neurologicaldisease and #brainhealth? Aries Biotech want to hear from you! Your perspective holds immense value for us and we recognize the vit

Aries Biotech extends gratitude to CSIRO, Australia's national science agency, for inviting Dr. Angela Boutte, the founder of Aries Biotech, to discuss health initiatives. At Aries Biotech, we believ

Revolutionizing Neuroscience and Neurotrauma: Aries Biotech Announces New Services Available to KOLs and Investors Aries Biotechnologies is thrilled to introduce

bottom of page